Abstract 110P
Background
Conversion therapy is an important treatment for patients with initial unresectable metastatic colorectal cancer(mCRC) to achieve radical resection. Circulating tumor cells (CTC) are one of the important liquid biopsy methods. There is no study to explore their clinical value in predicting the efficacy. The aim of this study is to explore the value of the number and morphology of CTC in predicting the efficacy of conversion therapy in initial unresectable mCRC patients.
Methods
This study prospectively collected eligible patients with initially unresectable mCRC who were initially diagnosed in Zhongshan Hospital from November 2020 to June 2021. At baseline, after treatment, and before and after conversion resection, multi-point blood sampling was performed. CTC detection using ChimeraX ® Platform; Morphological typing is based on the CTC morphological data of 2083 patients with colorectal cancer who underwent CTC detection in Zhongshan Hospital. Cell Profiler is used for cell feature assignment, clustering and typing.
Results
A total of 126 eligible patients with mCRC participated in this study. According to morphology, CTC can be divided into four morphological types: T1-T4. All 126 patients underwent baseline CTC testing, and 103 patients underwent CTC testing after conversion therapy. After conversion therapy, the positive rate and detection number of CTC significantly decreased (85.7% vs 60.2%, 1.71 vs 1.15, P=0.0052); The detection number of T3 and T4 subtypes significantly decreased (T3: 0.87 vs 0.52, P=0.0026, T4: 0.25 vs 0.06, P<0.0001). The objective response rate was significantly correlated with the baseline number of CTCs (69.8% vs 50.8%, P=0.029), but not significantly with the number of CTCs after treatment. The objective response rate of patients with T3T4 dominance was significantly higher than that of patients with T1T2 dominance (67.6% vs 47.1%, P=0.042). The number of CTC was correlated with patient progression free survival, and baseline CTC positive patients had a worse prognosis (P=0.0012).
Conclusions
The number and morphology of CTCs have good therapeutic and prognostic value for patients with initial unresectable mCRC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
571P - Dacomitinib in treatment-naïve EGFR-mutant NSCLC patients with multiple brain metastases: Initial efficacy and safety data from a phase II study
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
572P - Multivariable five-year survival prediction model for prognosing patients with EGFR-mutated NSCLC treated with EGFR-TKIs
Presenter: Qi-An Wang
Session: Poster Display
Resources:
Abstract
573P - LUMINATE-103: Real-world treatment patterns and outcomes of patients (pts) with epidermal growth factor receptor mutant (EGFR MU), non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC): Pooled analysis of large US electronic health record (EHR) datasets
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
574P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutations
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
575P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: A multicenter cohort study
Presenter: Puyuan Xing
Session: Poster Display
Resources:
Abstract
576P - Clonality of both EGFR and co-occurring TP53 mutations affect the treatment efficacy of the third-generation EGFR-TKIs in advanced-stage EGFR-mutant non-small cell lung cancer
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
577P - A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC
Presenter: Daeho Choi
Session: Poster Display
Resources:
Abstract
578P - Tyrosine kinase inhibitor treatment of elderly patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer: A multi-institute retrospective study
Presenter: Ling-Jen Hung
Session: Poster Display
Resources:
Abstract
579P - Real-world study of dacomitinib as first-line treatment for patients with EGFR-mutant non-small cell lung cancer
Presenter: Ji Eun Shin
Session: Poster Display
Resources:
Abstract
580P - Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor <italic>(EGFR)</italic> 21L858R mutation: A multicenter, ambispective, consecutive case-series study
Presenter: Shouzheng Wang
Session: Poster Display
Resources:
Abstract